A recent study has uncovered a potential game-changer in the realm of pediatric Crohn’s disease management—the microRNA (miRNA) molecule miR-29. Researchers have identified significant disparities in miR-29 levels when comparing intestinal samples from children with Crohn’s disease and their healthy counterparts, shedding light on a promising avenue for predicting disease severity and exploring new therapeutic targets. These groundbreaking findings have been documented in the journal JCI Insight.
Crohn’s disease, an inflammatory bowel disorder characterized by excruciating pain, severe diarrhea, malnutrition, and weight loss, poses substantial challenges in treatment and remission attainment, particularly in pediatric patients for whom the prevalence of the condition is steadily increasing worldwide. Professor Praveen Sethupathy, a distinguished figure in Physiological Genomics and chair of the Department of Biomedical Sciences at the College of Veterinary Medicine, spearheaded the study which manifested as a result of a longstanding collaboration with experts from the University of North Carolina, Chapel Hill.
While the impact of miRNAs in adult Crohn’s disease has been well-documented, there exists a scarcity of studies exploring their role in children. Sethupathy’s research, which delves into data from over 250 children, represents the most extensive miRNA analysis in pediatric Crohn’s disease to date, offering unparalleled insights into the alterations of microRNAs in this demographic. The study, facilitated by modern technological advancements in small RNA-sequencing, disclosed miR-29 as a standout player among the miRNAs present in the gut samples of afflicted children.
Distinctively elevated levels of miR-29 were observed in children with Crohn’s disease compared to their healthy counterparts, setting pediatric Crohn’s disease apart from its adult counterpart in terms of miRNA expression patterns. This aberrant surge in miR-29 levels was found to correlate with increased inflammation, disease severity, and a decline in Paneth cells—an essential component in safeguarding the gut against harmful bacterial infiltration.
Interestingly, the study also uncovered an association between higher miR-29 levels and the depletion of Paneth cells, a link further validated in mouse models. The loss of these crucial gut-residing cells upon miR-29 upregulation underscores the profound impact of this particular microRNA in orchestrating inflammatory responses within the gut environment.
Additionally, the study sheds light on other miRNA alterations, such as miR-375, that hold promise in unraveling new therapeutic targets for both pediatric and adult Crohn’s disease. Sethupathy is optimistic that this study marks a pivotal milestone in the quest to identify key disease regulators beyond miR-29, opening doors to novel therapeutic interventions and deeper mechanistic insights in the management of Crohn’s disease.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research.
2. We have leveraged AI tools to mine information and compile it.
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.